We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Veru has enrolled the first subject in Phase III clinical trial of sabizabulin to treat hospitalised Covid-19 patients who are at high risk for acute respiratory distress syndrome (ARDS).